<DOC>
	<DOCNO>NCT02234960</DOCNO>
	<brief_summary>The aim non-interventional , prospective , observational study ass effectiveness tolerability RoActemra ( tocilizumab ) use first-line biologic treatment participant moderate severe active RA inadequate responder disease-modifying antirheumatic drug ( DMARDs ) , participant intolerant DMARDs , routine clinical practice set Poland . The length entire study 24 month .</brief_summary>
	<brief_title>Local , Non-Interventional Study RoActemra ( Tocilizumab ) Poland ( ACT-POL ) : First-Line Treatment Routine Clinical Practice Participants With Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>participant least 18 year age diagnosis moderate severe RA treating physician make decision commence tocilizumab first line biologic treatment ( population DMARDs inadequate responder participant intolerant DMARDs ) routine clinical practice Poland inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>